secwatch.observer — SEC 8-K summary
======================================

Issuer:     Silexion Therapeutics Corp (SLXN)
CIK:        0002022416
Form:       8-K
Filed at:   2026-08-21T20:21:14+00:00
Accession:  0001178913-26-004223
Event type: regulatory
Sentiment:  negative
Materiality: 0.90
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

Silexion receives Nasdaq delisting notice for equity shortfall; plans appeal
----------------------------------------------------------------------------

- Nasdaq delisting notice received Aug 18, 2026 for failure to meet $2.5M shareholders' equity requirement (Rule 5550(b)(1)).
- Shareholders' equity as of June 30, 2026 was only $44,000, far below required minimum.
- Company intends to appeal by Aug 25, 2026; under Mandatory Hearings Panel Monitor limiting compliance extensions.
- If appeal fails, ordinary shares and warrants (SLXN, SLXNW) will be suspended and delisted via Form 25-NSE.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2022416/000117891326004223/0001178913-26-004223-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2022416/000117891326004223/zk2635995.htm
  HTML page:      https://secwatch.observer/filing/0001178913-26-004223

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer